Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shot up 27.1% on Tuesday . The stock traded as high as $9.45 and last traded at $9.05, with a volume of 1,809,335 shares traded. The stock had previously closed at $7.12.

Several research firms have recently weighed in on KPTI. Canaccord Genuity set a $20.00 target price on shares of Karyopharm Therapeutics and gave the stock a “buy” rating in a report on Saturday, August 6th. Leerink Swann reaffirmed a “buy” rating on shares of Karyopharm Therapeutics in a report on Sunday, June 12th. Vetr lowered shares of Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating and set a $11.00 target price on the stock. in a report on Wednesday. Zacks Investment Research lowered shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 12th. Finally, HC Wainwright began coverage on shares of Karyopharm Therapeutics in a report on Thursday, August 18th. They issued a “buy” rating and a $15.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating and eleven have given a buy rating to the company. Karyopharm Therapeutics has an average rating of “Buy” and an average target price of $15.97.

The stock’s 50-day moving average price is $7.35 and its 200-day moving average price is $7.97. The firm’s market cap is $358.09 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Thursday, August 4th. The company reported ($0.84) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.08. Analysts anticipate that Karyopharm Therapeutics Inc. will post ($3.26) earnings per share for the current year.

In related news, major shareholder Ltd Chione sold 18,824 shares of the business’s stock in a transaction dated Thursday, June 23rd. The stock was sold at an average price of $8.03, for a total value of $151,156.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.